90 reports of this reaction
3.5% of all BUPRENORPHINE AND NALOXONE reports
#4 most reported adverse reaction
INJECTION SITE REACTION is the #4 most commonly reported adverse reaction for BUPRENORPHINE AND NALOXONE, manufactured by Amneal Pharmaceuticals LLC. There are 90 FDA adverse event reports linking BUPRENORPHINE AND NALOXONE to INJECTION SITE REACTION. This represents approximately 3.5% of all 2,589 adverse event reports for this drug.
Patients taking BUPRENORPHINE AND NALOXONE who experience injection site reaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE REACTION is moderately reported among BUPRENORPHINE AND NALOXONE users, representing a notable but not dominant share of adverse events.
In addition to injection site reaction, the following adverse reactions have been reported for BUPRENORPHINE AND NALOXONE:
The following drugs have also been linked to injection site reaction in FDA adverse event reports:
INJECTION SITE REACTION has been reported as an adverse event in 90 FDA reports for BUPRENORPHINE AND NALOXONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE REACTION accounts for approximately 3.5% of all adverse event reports for BUPRENORPHINE AND NALOXONE, making it a notable side effect.
If you experience injection site reaction while taking BUPRENORPHINE AND NALOXONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.